The third most cited study, “HLA-DR2 Dose Effect on Susceptibility to Multiple Sclerosis and Influence on Disease Course” (Barcellos et al., 2003), found that individuals with two copies of HLA-DRB1*15:01 had a significantly higher MS risk and worse disease progression. Here, HLA-DRB1 is linked to myeloid sarcoma.